Home Ingredients LAFTI® L10 (Lactobacillus helveticus Lafti L10, also published as L. acidophilus LAFTI L10)

LAFTI® L10 (Lactobacillus helveticus Lafti L10, also published as L. acidophilus LAFTI L10)

Lactobacillus helveticus
Evidence Level
Limited
6 Clinical Trials
6 Documented Benefits
2/5 Evidence Score

LAFTI L10 is a single probiotic lactobacillus strain that food studies list as Lactobacillus acidophilus LAFTI L10 from DSM Food Specialties in Australia. Trials since 2016 that obtained it from Lallemand Health Solutions name it Lactobacillus helveticus Lafti L10, so labels may use either species name. In a 14 week winter trial in 39 elite athletes, 20 billion CFU a day was followed by shorter cold-like symptom episodes than placebo, though the number and severity of episodes did not differ. In recreational runners, 6 weeks did not improve endurance compared with placebo. In infants of allergic mothers, 6 months of the strain (under the code LAVRI-A1) did not lower skin allergy rates and was linked to more allergen sensitization at 1 year. A French bowel trial paired it with the NCFM strain, so that result belongs to the blend.

Studied Dose 20 billion CFU once daily for 14 weeks (elite athletes); 5 billion CFU once daily for 6 weeks (recreational runners); 3 billion CFU daily for the first 6 months of life (infants). Blend with NCFM: two 5 billion CFU capsules a day for 8 weeks.
Active Compound Live lactobacillus strain LAFTI L10, freeze-dried, in capsules. Food studies named DSM Food Specialties (Sydney, Australia) as the supplier of L. acidophilus LAFTI L10; an infant trial used the strain as L. acidophilus LAVRI-A1 from Probiomics; trials from 2016 onward name it L. helveticus Lafti L10 from Lallemand Health Solutions (Montreal). No culture collection deposit number was found in the sources read.

Benefits

Immune defense during winter training in elite athletes

In 39 elite athletes given 20 billion CFU a day or placebo for 14 winter weeks, cold-like symptom episodes lasted about 7 days versus 11 on placebo (p = 0.047), and fewer symptoms were reported. How often episodes occurred and how severe they were did not differ, and the published summary named no single main outcome. The trial was small and has not been repeated.

Supported by Trial 1, Trial 4

Antibody levels in blood and saliva of athletes

In 30 athletes over 14 weeks, total IgA in serum and saliva fell on placebo but not on the probiotic, and some IgA and IgG antibodies to specific bacteria were higher than on placebo. Total IgM rose in both groups. These are lab markers, not proof of fewer illnesses.

Supported by Trial 2, Trial 3

Oxidative stress markers in endurance athletes

In 22 male endurance athletes over 14 weeks, two blood markers of oxidative damage, malondialdehyde and oxidized proteins, fell on the probiotic and not on placebo. Total antioxidant status and most other measures did not change. These are blood markers, not a performance or health outcome.

Supported by Trial 3, Trial 2

Endurance capacity in recreational runners

In 28 recreational runners, 5 billion CFU a day for 6 weeks did not improve time to exhaustion on a treadmill. Time rose on placebo and not on the probiotic, and the probiotic group trained less often and less hard during the study. Stomach and cold symptoms were few in both groups.

Supported by Trial 4, Trial 1

Infant immune development and allergen sensitization

Newborns of allergic mothers took 3 billion CFU a day or placebo for 6 months. Skin allergy rates did not differ at 6 or 12 months or at 2.5 years, and skin test sensitization at 1 year was more common on the probiotic. Fewer stomach infections were reported in the probiotic group at the 2.5 year review.

Supported by Trial 5

Gas and overall bowel scores with the NCFM plus LAFTI L10 blend

In 80 adults with IBS, a blend of NCFM and LAFTI L10 at 10 billion CFU a day for 8 weeks did not beat placebo on abdominal pain, the main outcome, but lowered flatus and a composite symptom score. The result belongs to the two-strain blend, not LAFTI L10 alone.

Supported by Trial 1, Trial 4

Mechanism of action

1

Gene activity in the human small intestine lining

In 7 healthy adults in a placebo-controlled crossover study, a single 6 hour dosing of L. acidophilus Lafti L10 changed gene networks that regulate basic processes of the lining in duodenal biopsies, with a pattern different from L. casei and L. rhamnosus. This is a short-term marker study, not a health outcome.

2

Gut and systemic immune cells in mice (animal work)

Mice fed LAFTI L10 for 14 days had more IgA, IL-10 and interferon-gamma producing cells in the small intestine, more active spleen cells and peritoneal macrophages, and no spread of bacteria to the spleen, liver or blood. These are animal findings only.

3

Cytokine responses in infants (marker work)

In the infant trial, 6 months of the strain lowered some cytokine responses to a tetanus vaccine antigen and to house dust mite, but did not change allergen-specific Th1 or Th2 responses. The clinical meaning of these marker shifts is unknown.

Clinical trials

1
Lafti L10 vs Placebo for 14 Winter Weeks in Elite Athletes
PubMed

Randomized, double-blind, placebo-controlled trial in Serbia; L. helveticus Lafti L10 (Lallemand Health Solutions) at 20 billion CFU a day or placebo for 14 weeks in winter; stated aims were the duration, severity and incidence of upper respiratory tract illness plus immune parameters, with no single primary outcome named in the abstract (the full text could not be read), and the duration result (p = 0.047) would not pass a correction for these three illness outcomes; the group's 2017 antibody and 2018 oxidative stress papers used the same 14 week design and do not say whether their athletes overlap with this sample; no trial registration and no funding statement in the abstract; authors from the University of Belgrade, the Torlak institute and the Sports Medicine Association of Serbia, with no Lallemand employees listed (Michalickova et al. 2016, Appl Physiol Nutr Metab)

39 elite athletes (20 probiotic, 19 placebo).

Episodes were shorter on the probiotic (7.25 versus 10.64 days, p = 0.047) with fewer symptoms (4.92 versus 6.91, p = 0.035). Severity and incidence did not differ. Most blood immune measures did not change; the CD4 to CD8 ratio differed between groups at 14 weeks, and self-rated vigor rose on the probiotic.

2
Lafti L10 vs Placebo: Antibodies in Athletes Over 14 Weeks
PubMed

Randomized, double-blind, placebo-controlled trial by the same Belgrade group with the same 14 week design (the abstract prints the dose without its exponent; the group's other papers used 20 billion CFU a day); outcomes were total and bacteria-specific antibodies in serum and saliva; the papers do not say whether the athletes overlap with the 39 person trial; no funding statement or registration in the abstract (Michalickova et al. 2017, J Strength Cond Res)

30 athletes (24 men, 6 women), mean age about 24.

Total IgM rose in both groups with no between-group difference, and total IgG did not change. Total IgA fell on placebo in serum (15%) and saliva (35%) but not on the probiotic, and serum IgA to two L. rhamnosus strains and IgG to E. faecalis were lower on placebo than on the probiotic. These are antibody markers only; no illness outcome was reported.

3
Lafti L10 vs Placebo: Oxidative Stress Markers in 22 Endurance Athletes
PubMed

Randomized, double-blind, placebo-controlled parallel trial in Serbia; L. helveticus Lafti L10 at 20 billion CFU a day or maltodextrin placebo for 14 weeks; outcomes were blood markers of oxidative stress and antioxidant defense; 22 athletes finished the study, and the paper does not say whether they overlap with the group's 39 and 30 athlete reports; Lallemand Health Solutions supplied the probiotic and placebo capsules, and funding came from the Serbian science ministry and Charles University; no company authors (Michalickova et al. 2018, J Hum Kinet)

22 male triathletes, cyclists and middle and long distance runners (10 probiotic, 12 placebo).

Malondialdehyde (interaction p = 0.039) and advanced oxidation protein products (interaction p = 0.037) fell in the probiotic group only. Superoxide dismutase fell on the probiotic (interaction p = 0.108), paraoxonase fell in both groups, and total antioxidant status, total oxidant status and the other measures did not change. These are blood markers only.

4
Lafti L10 vs Placebo for 6 Weeks: Running Endurance, No Benefit
PubMed

Randomized, placebo-controlled, double-blind parallel trial at the University of Florida; L. helveticus Lafti L10 at 5 billion CFU in one capsule a day or placebo for 6 weeks; primary outcome time to exhaustion at 85% of VO2max on a treadmill, with daily gastrointestinal and cold or flu symptom diaries; the authors reported no conflicts of interest and the abstract gives no funding source or registration (McDermott et al. 2024, Appl Physiol Nutr Metab)

28 generally healthy recreational runners who completed the study (14 per group), mean age 25.

Time to exhaustion at the final visit was lower on the probiotic than placebo (p = 0.01) because it rose on placebo (1344 to 1565 s) and did not change on the probiotic. The probiotic group completed fewer aerobic sessions a week (p = 0.02) at lower intensity (p = 0.007). Few stomach or cold symptoms were reported, with no difference between groups.

5
L. acidophilus LAVRI-A1 (LAFTI L10) vs Placebo for 6 Months in Infants of Allergic Mothers
PubMed

Randomized, placebo-controlled trial in Perth, Australia; newborns took 3 billion CFU of L. acidophilus LAVRI-A1 (Probiomics) or maltodextrin placebo daily for the first 6 months of life; outcomes were atopic dermatitis and other symptoms at 6 and 12 months and skin prick tests at 12 months; the 2.5 year follow-up paper names the strain LAFTI L10/LAVRI-A1; university authors, with no funding source stated in the abstracts read (Taylor et al. 2007, J Allergy Clin Immunol)

231 newborns of women with allergy were randomized; 178 completed supplementation, and 153 were reviewed at 2.5 years.

Skin allergy rates did not differ at 6 months (25.8% versus 22.7%, p = 0.629) or 12 months, and sensitization at 12 months was more common on the probiotic (p = 0.030). At 2.5 years, rates still did not differ (42% versus 34%), while the probiotic group had fewer stomach infections over the preceding 18 months (p = 0.023), a secondary finding.

6
Lafti L10 vs Placebo: Small Intestine Gene Activity in 7 Adults (Crossover)
PubMed

Randomized, double-blind, placebo-controlled crossover study in the Netherlands; on separate days each volunteer took freeze-dried L. acidophilus Lafti L10, L. casei or L. rhamnosus every 30 minutes for 6 hours (about 52 billion L. acidophilus in total) or placebo, with a 2 week washout, followed by duodenal biopsies; funded by Dutch public genomics and bioinformatics programs, and the authors declared no conflicts (van Baarlen et al. 2011, Proc Natl Acad Sci U S A)

7 healthy nonsmoking adults, mean age 24.

Each strain changed a different set of gene networks that regulate basic processes in the lining of the small intestine compared with placebo. The study measured gene activity only, after a single day of dosing, and reported no health or symptom outcomes.

Side effects and drug interactions

Common Potential side effects

In infants of allergic mothers, 6 months of the strain did not lower skin allergy rates and was followed by more allergen sensitization on skin tests at 1 year than placebo; it should not be given to infants without a pediatrician's advice.
In recreational runners taking 5 billion CFU a day for 6 weeks, few stomach or cold symptoms were reported, with no difference from placebo.
Lactobacilli, including L. acidophilus, have rarely caused bloodstream and heart valve infections, mostly in immunocompromised or diabetic people; people who are severely immunocompromised or critically ill should check with a doctor before using live probiotics.
Adult trials lasted 6 to 14 weeks, so longer-term data on this strain in adults are lacking.

Important Drug interactions

Antibiotics: no trial tested LAFTI L10 alongside antibiotics. Antibiotics can kill live bacteria, so ask your pharmacist about spacing a probiotic from antibiotic doses.
Immunosuppressants and chemotherapy: people taking drugs that weaken the immune system should use live probiotics only with medical advice.
No drug interaction studies of LAFTI L10 were found among the cited sources. Tell your doctor or pharmacist about any supplement you take.

Explore Other Ingredients

Bone Health
Collagen
Collagen is the main structural protein of skin, bone, cartilage, tendons and ligaments. S…
Hair, Skin & Nails
Hyaluronic Acid
Hyaluronic acid is a naturally occurring substance in the body, primarily found in connect…
Hair, Skin & Nails
Astaxanthin
Astaxanthin is a red-orange carotenoid antioxidant. It is naturally produced by the microa…

Frequently asked questions about LAFTI® L10 (Lactobacillus helveticus Lafti L10, also published as L. acidophilus LAFTI L10)

Is LAFTI L10 an acidophilus or a helveticus strain?

Both names appear. Earlier papers, which obtained it from DSM, called it Lactobacillus acidophilus LAFTI L10, and an infant trial used it under the code LAVRI-A1. Trials since 2016 that obtained it from Lallemand Health Solutions call it Lactobacillus helveticus Lafti L10. It is a different strain from NCFM, DDS-1 and LA-5.

What has LAFTI L10 been studied for on its own?

In 39 elite athletes, 14 winter weeks were followed by shorter cold-like symptom episodes than placebo, but not fewer episodes. Related papers from that group reported antibody and oxidative stress marker changes. In recreational runners it did not improve endurance, and in infants it did not lower skin allergy rates.

How much LAFTI L10 was used in studies?

Adult trials used 20 billion CFU once a day for 14 weeks in elite athletes and 5 billion CFU once a day for 6 weeks in runners. A French bowel trial used 10 billion CFU a day of a blend with the NCFM strain. Follow the product label and ask a healthcare provider for personal advice.

Is LAFTI L10 safe?

Published summaries of the adult trials, which lasted up to 14 weeks, reported no safety problems, and the authors of the 8 week blend trial concluded the blend was safe. In infants of allergic mothers, it was followed by more allergen sensitization at 1 year, so it should not be given to infants without a pediatrician's advice. As with all lactobacilli, people who are severely immunocompromised or critically ill should ask a doctor first.

What is LAFTI L10?

LAFTI L10 is a single probiotic lactobacillus strain that food studies list as Lactobacillus acidophilus LAFTI L10 from DSM Food Specialties in Australia. Trials since 2016 that obtained it from Lallemand Health Solutions name it Lactobacillus helveticus Lafti L10, so labels may use either species name.

What is LAFTI L10 used for?

NutraSmarts does not list LAFTI L10 under a health category. What the research covers: In 39 elite athletes given 20 billion CFU a day or placebo for 14 winter weeks, cold-like symptom episodes lasted about 7 days versus 11 on placebo (p = 0.047), and fewer symptoms were reported.

Does LAFTI L10 interact with any medications?

Possible interactions include: Antibiotics: no trial tested LAFTI L10 alongside antibiotics. Antibiotics can kill live bacteria, so ask your pharmacist about spacing a probiotic from antibiotic doses. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for LAFTI L10?

NutraSmarts rates the evidence for LAFTI L10 as Limited (2 out of 5). It is backed by 6 study summaries and 15 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(15 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Michalickova D, Minic R, Dikic N, Andjelkovic M, Kostic-Vucicevic M, Stojmenovic T, Nikolic I, Djordjevic B. Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. Appl Physiol Nutr Metab. 2016;41(7):782-9. doi: 10.1139/apnm-2015-0541.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 39 elite athletes: L. helveticus Lafti L10 (Lallemand Health Solutions) at 2 x 10^10 CFU a day or placebo for 14 winter weeks. Upper respiratory illness episodes were shorter (7.25 versus 10.64 days, p = 0.047) with fewer symptoms (p = 0.035); severity and incidence did not differ. Most immune cell and cytokine measures did not change; the CD4+/CD8+ ratio differed at 14 weeks and self-rated vigor rose on the probiotic. No funding statement or registration in the abstract.
  2. Michalickova DM, Kostic-Vucicevic MM, Vukasinovic-Vesic MD, Stojmenovic TB, Dikic NV, Andjelkovic MS, Djordjevic BI, Tanaskovic BP, Minic RD. Lactobacillus helveticus Lafti L10 Supplementation Modulates Mucosal and Humoral Immunity in Elite Athletes: A Randomized, Double-Blind, Placebo-Controlled Trial. J Strength Cond Res. 2017;31(1):62-70. doi: 10.1519/JSC.0000000000001456.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 30 athletes over 14 weeks of L. helveticus Lafti L10 or placebo. Total IgM rose in both groups without a between-group difference; total IgG was constant; total IgA fell on placebo in serum and saliva, and some bacteria-specific IgA and IgG were lower on placebo than on the probiotic. Antibody markers only.
  3. Michalickova D, Kotur-Stevuljevic J, Miljkovic M, Dikic N, Kostic-Vucicevic M, Andjelkovic M, Koricanac V, Djordjevic B. Effects of Probiotic Supplementation on Selected Parameters of Blood Prooxidant-Antioxidant Balance in Elite Athletes: A Double-Blind Randomized Placebo-Controlled Study. J Hum Kinet. 2018;64:111-122. doi: 10.1515/hukin-2017-0203.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 22 male elite endurance athletes: L. helveticus Lafti L10 (Lallemand Health Solutions) at 2 x 10^10 CFU a day or placebo for 14 weeks. Malondialdehyde and advanced oxidation protein products fell in the probiotic group only (interaction p = 0.039 and 0.037); most other oxidative and antioxidant markers did not change. The full text states Lallemand supplied the probiotic and placebo capsules and that the work was funded by the Serbian science ministry and Charles University.
  4. McDermott CE, Judkins TC, Vincent HK, Culpepper T, Colee J, Nieves C Jr, Mathews AE, Langkamp-Henken B. Impact of probiotic supplementation on exercise endurance among nonelite athletes: a randomized, placebo-controlled, double-blind, clinical trial. Appl Physiol Nutr Metab. 2024;49(10):1377-1386. doi: 10.1139/apnm-2024-0142.PubMedUsed to support: Randomized, placebo-controlled, double-blind trial in 28 recreational runners: L. helveticus Lafti L10 at 5 x 10^9 CFU a day or placebo for 6 weeks. Time to exhaustion at the final visit was lower on the probiotic (p = 0.01) because it rose on placebo and not on the probiotic; the probiotic group trained less often and at lower intensity. Gastrointestinal and cold or flu symptoms were few, with no group difference. The authors reported no conflicts of interest.
  5. Taylor AL, Dunstan JA, Prescott SL. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial. J Allergy Clin Immunol. 2007;119(1):184-91. doi: 10.1016/j.jaci.2006.08.036.PubMedUsed to support: Randomized controlled trial in 231 newborns of allergic mothers (178 completed): L. acidophilus LAVRI-A1 or placebo daily for the first 6 months. Atopic dermatitis rates did not differ at 6 months (25.8% versus 22.7%) or 12 months, and allergen sensitization at 12 months was higher on the probiotic (p = 0.030). Lactobacillus colonization was higher on the probiotic.
  6. Prescott SL, Wiltschut J, Taylor A, Westcott L, Jung W, Currie H, Dunstan JA. Early markers of allergic disease in a primary prevention study using probiotics: 2.5-year follow-up phase. Allergy. 2008;63(11):1481-90. doi: 10.1111/j.1398-9995.2008.01778.x.PubMedUsed to support: 2.5 year follow-up of 153 children from the same infant trial, which names the strain as L. acidophilus LAFTI L10/LAVRI-A1. Dermatitis at 2.5 years did not differ (42% versus 34% on placebo), and no other allergic outcome or sensitization was reduced; children who had received the probiotic had fewer gastrointestinal infections in the preceding 18 months (P = 0.023).
  7. Taylor AL, Hale J, Wiltschut J, Lehmann H, Dunstan JA, Prescott SL. Effects of probiotic supplementation for the first 6 months of life on allergen- and vaccine-specific immune responses. Clin Exp Allergy. 2006;36(10):1227-35. doi: 10.1111/j.1365-2222.2006.02553.x.PubMedUsed to support: Immune marker analysis from the same infant trial: 3 x 10^9 L. acidophilus LAVRI-A1 (Probiomics) or maltodextrin placebo daily for 6 months. Infants on the probiotic had lower IL-5 and TGF-beta responses to polyclonal stimulation, lower IL-10 responses to tetanus toxoid, and lower TNF-alpha and IL-10 responses to house dust mite, without effects on Th1 or Th2 responses to allergens.
  8. van Baarlen P, Troost F, van der Meer C, Hooiveld G, Boekschoten M, Brummer RJ, Kleerebezem M. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc Natl Acad Sci U S A. 2011;108 Suppl 1(Suppl 1):4562-9. doi: 10.1073/pnas.1000079107.PubMedUsed to support: Double-blind, placebo-controlled crossover study in 7 healthy adults: L. acidophilus (Lafti L10 per the full text), L. casei and L. rhamnosus were each given over 6 hours before duodenal biopsies. Each strain induced different gene-regulatory networks in the small intestine lining. Gene activity markers only; the authors declared no conflict of interest.
  9. Sadrin S, Sennoune SR, Gout B, Marque S, Moreau J, Grillasca J, Pons O, Maixent JM. Lactobacillus acidophilus versus placebo in the symptomatic treatment of irritable bowel syndrome: the LAPIBSS randomized trial. Cell Mol Biol (Noisy-le-grand). 2017;63(9):122-131. doi: 10.14715/cmb/2017.63.9.21.PubMedUsed to support: Other product (two-strain blend). Published protocol of the LAPIBSS trial: a mixture of L. acidophilus NCFM and LAFTI L10 at 5 x 10^9 CFU per capsule, two capsules a day, or placebo for 8 weeks in 80 adults with IBS, with abdominal pain on a 100 mm scale as the primary outcome. Names the two strains. Registered EudraCT 2008-A00844-51.
  10. Sadrin S, Sennoune S, Gout B, Marque S, Moreau J, Zinoune K, Grillasca JP, Pons O, Maixent JM. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. Dig Liver Dis. 2020;52(5):534-540. doi: 10.1016/j.dld.2019.12.009.PubMedUsed to support: Other product (two-strain blend). Results of LAPIBSS in 80 adults with IBS: abdominal pain, the primary outcome, did not differ from placebo at week 8 (p = 0.06); flatus (weeks 4 and 8) and a composite score (week 8) were lower than on placebo. The first author also listed an affiliation with Laboratoire Denel-Codifra.
  11. Schreiber C, Tamir S, Golan R, Weinstein A, Weinstein Y. The effect of probiotic supplementation on performance, inflammatory markers and gastro-intestinal symptoms in elite road cyclists. J Int Soc Sports Nutr. 2021;18(1):36. doi: 10.1186/s12970-021-00432-6.PubMedUsed to support: Other product (five-strain blend). Randomized, double-blind trial in 27 elite male cyclists of a 15 billion CFU blend in which L. helveticus Lafti L10 was 28.6%, with Lafti B94, E. faecium R0026, B. longum R0175 and B. subtilis R0179, for 90 days. Some gastrointestinal symptoms and perceived exertion were lower than on placebo; VO2max, time to fatigue and inflammatory markers did not change. Funded by Altman Health Israel and Tel Hai Academic College. Registered NCT02756221.
  12. Paturi G, Phillips M, Jones M, Kailasapathy K. Immune enhancing effects of Lactobacillus acidophilus LAFTI L10 and Lactobacillus paracasei LAFTI L26 in mice. Int J Food Microbiol. 2007;115(1):115-8. doi: 10.1016/j.ijfoodmicro.2006.10.007.PubMedUsed to support: Animal study. BALB/c mice fed L. acidophilus LAFTI L10 at 10^8 CFU a day for 14 days had more IgA, IL-10 and interferon-gamma producing cells in the small intestine and higher serum IL-10 and interferon-gamma. Not a human study.
  13. Paturi G, Phillips M, Kailasapathy K. Effect of probiotic strains Lactobacillus acidophilus LAFTI L10 and Lactobacillus paracasei LAFTI L26 on systemic immune functions and bacterial translocation in mice. J Food Prot. 2008;71(4):796-801. doi: 10.4315/0362-028x-71.4.796.PubMedUsed to support: Animal study. In mice fed L. acidophilus LAFTI L10 for 14 days, spleen cell proliferation and peritoneal macrophage phagocytic activity rose, with no bacterial translocation to the spleen, liver or blood. Not a human study.
  14. Tavakoli M, Habibi Najafi MB, Mohebbi M. Effect of the milk fat content and starter culture selection on proteolysis and antioxidant activity of probiotic yogurt. Heliyon. 2019;5(2):e01204. doi: 10.1016/j.heliyon.2019.e01204.PubMedUsed to support: Food science study, not a human trial. Its methods state that the probiotic was Lactobacillus acidophilus LAFTI L10, supplied with the starter cultures in freeze-dried form by DSM Food Specialties (Sydney, NSW, Australia); cited here only for the strain's original supplier and species name.
  15. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli Infection Case Reports in the Last Three Years and Safety Implications. Nutrients. 2022;14(6):1178. doi: 10.3390/nu14061178.PubMedUsed to support: Review of lactobacilli infection case reports from 2019 to 2021 (17, 15 and 16 cases a year), including endocarditis and bacteremia, mostly in diabetic and immunocompromised people with risk factors; L. acidophilus accounted for 5 cases. Not specific to LAFTI L10.